Skip to content

Pfizer’s Paxlovid to Be Studied as Potential Long Covid Therapy

A box of Pfizer’s Paxlovid antiviral medication.
A box of Pfizer’s Paxlovid antiviral medication.Photographer: Kobi Wolf/Bloomberg

Pfizer Inc.’s antiviral Paxlovid will be tested in a late-stage trial as a treatment for long Covid.

The yearlong study is slated to start in January and involve 1,700 participants, according to information posted on a US government website on Thursday. It will investigate whether 15 days of treatment twice daily improves symptoms and function, including exercise tolerance, three months later.